Biological and Pharmaceutical Bulletin, volume 41, issue 5, pages 722-732

Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures

YOKOYAMA Yuichi 1, 2
Sasaki Yoshifumi 1
Terasaki Natsuko 1
Kawataki Taku 1
Takekawa Koji 1
Iwase Yumiko 1
Shimizu Toshinobu 1
Sanoh Seigo 2
Ohta Shigeru 2
1
 
Safety Research Laboratories, Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
2
 
Graduate School of Biomedical and Health Sciences, Hiroshima University
Publication typeJournal Article
Publication date2018-02-13
Quartile SCImago
Q2
Quartile WOS
Q4
Impact factor2
ISSN09186158, 13475215
General Medicine
Pharmacology
Pharmaceutical Science
Abstract
Differentiated HepaRG cells maintain liver-specific functions such as drug-metabolizing enzymes. In this study, the feasibility of HepaRG cells as a human hepatocyte model for in vitro toxicity assessment was examined using selected hepatotoxic compounds. First, basal drug-metabolizing enzyme activities (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, uridine 5'-diphospho-glucuronosyltransferase [UGT], and sulfotransferases [SULT]) were measured in HepaRG, human hepatocytes, and HepG2 cells. Enzyme activities in differentiated HepaRG cells were comparable to those in human hepatocytes and much higher than those in HepG2 cells, except for SULT activity. Second, we examined the cytotoxicity of hepatotoxic compounds, acetaminophen (APAP), aflatoxin B1 (AFB1), cyclophosphamide (CPA), tamoxifen (TAM), and troglitazone (TGZ) in HepaRG cells and human hepatocytes. AFB1- and CPA-induced cytotoxicities against HepaRG cells were comparable to those against human hepatocytes. Furthermore, the cytotoxicities of these compounds were inhibited by 1-aminobenzotriazole (ABT), a broad CYP inhibitor, in both cells and were likely mediated by metabolic activation by CYP. Finally, toxicogenomics analysis of HepG2 and HepaRG cells after exposure to AFB1 and CPA revealed that numerous p53-related genes were upregulated- and the expression of these genes was greater in HepaRG than in HepG2 cells. These results suggest that gene expression profiles of HepaRG cells were affected more considerably by the toxic mechanisms of AFB1 and CPA than the profiles of HepG2 cells were. Therefore, our investigation shows that HepaRG cells could be useful human hepatic cellular models for toxicity studies.

Citations by journals

1
2
3
4
5
6
7
Toxicology in Vitro
Toxicology in Vitro, 7, 6.86%
Toxicology in Vitro
7 publications, 6.86%
Archives of Toxicology
Archives of Toxicology, 5, 4.9%
Archives of Toxicology
5 publications, 4.9%
Frontiers in Pharmacology
Frontiers in Pharmacology, 4, 3.92%
Frontiers in Pharmacology
4 publications, 3.92%
Scientific Reports
Scientific Reports, 4, 3.92%
Scientific Reports
4 publications, 3.92%
Toxicology
Toxicology, 3, 2.94%
Toxicology
3 publications, 2.94%
Current Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology, 2, 1.96%
Current Pharmaceutical Biotechnology
2 publications, 1.96%
Cells
Cells, 2, 1.96%
Cells
2 publications, 1.96%
Pharmaceuticals
Pharmaceuticals, 2, 1.96%
Pharmaceuticals
2 publications, 1.96%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 2, 1.96%
International Journal of Molecular Sciences
2 publications, 1.96%
Toxicology Reports
Toxicology Reports, 2, 1.96%
Toxicology Reports
2 publications, 1.96%
Journal of Pharmacological and Toxicological Methods
Journal of Pharmacological and Toxicological Methods, 2, 1.96%
Journal of Pharmacological and Toxicological Methods
2 publications, 1.96%
Food and Chemical Toxicology
Food and Chemical Toxicology, 2, 1.96%
Food and Chemical Toxicology
2 publications, 1.96%
Toxicology Mechanisms and Methods
Toxicology Mechanisms and Methods, 2, 1.96%
Toxicology Mechanisms and Methods
2 publications, 1.96%
Drug Metabolism Reviews
Drug Metabolism Reviews, 2, 1.96%
Drug Metabolism Reviews
2 publications, 1.96%
Toxicological Sciences
Toxicological Sciences, 2, 1.96%
Toxicological Sciences
2 publications, 1.96%
Doklady Biochemistry and Biophysics
Doklady Biochemistry and Biophysics, 1, 0.98%
Doklady Biochemistry and Biophysics
1 publication, 0.98%
Drug Metabolism and Disposition
Drug Metabolism and Disposition, 1, 0.98%
Drug Metabolism and Disposition
1 publication, 0.98%
Pharmacological Reviews
Pharmacological Reviews, 1, 0.98%
Pharmacological Reviews
1 publication, 0.98%
Journal of Cellular Biotechnology
Journal of Cellular Biotechnology, 1, 0.98%
Journal of Cellular Biotechnology
1 publication, 0.98%
World Chinese Journal of Digestology, 1, 0.98%
World Chinese Journal of Digestology
1 publication, 0.98%
Biomedicines
Biomedicines, 1, 0.98%
Biomedicines
1 publication, 0.98%
Molecules
Molecules, 1, 0.98%
Molecules
1 publication, 0.98%
Biomolecules
Biomolecules, 1, 0.98%
Biomolecules
1 publication, 0.98%
Cancers
Cancers, 1, 0.98%
Cancers
1 publication, 0.98%
Applied Sciences (Switzerland)
Applied Sciences (Switzerland), 1, 0.98%
Applied Sciences (Switzerland)
1 publication, 0.98%
Human Cell
Human Cell, 1, 0.98%
Human Cell
1 publication, 0.98%
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 1, 0.98%
Journal of Cancer Research and Clinical Oncology
1 publication, 0.98%
AMB Express
AMB Express, 1, 0.98%
AMB Express
1 publication, 0.98%
Forensic Toxicology
Forensic Toxicology, 1, 0.98%
Forensic Toxicology
1 publication, 0.98%
1
2
3
4
5
6
7

Citations by publishers

5
10
15
20
25
30
Elsevier
Elsevier, 28, 27.45%
Elsevier
28 publications, 27.45%
Springer Nature
Springer Nature, 14, 13.73%
Springer Nature
14 publications, 13.73%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 12, 11.76%
Multidisciplinary Digital Publishing Institute (MDPI)
12 publications, 11.76%
Taylor & Francis
Taylor & Francis, 8, 7.84%
Taylor & Francis
8 publications, 7.84%
Wiley
Wiley, 7, 6.86%
Wiley
7 publications, 6.86%
American Chemical Society (ACS)
American Chemical Society (ACS), 7, 6.86%
American Chemical Society (ACS)
7 publications, 6.86%
Frontiers Media S.A.
Frontiers Media S.A., 4, 3.92%
Frontiers Media S.A.
4 publications, 3.92%
Oxford University Press
Oxford University Press, 3, 2.94%
Oxford University Press
3 publications, 2.94%
American Society for Pharmacology and Experimental Therapeutics
American Society for Pharmacology and Experimental Therapeutics, 2, 1.96%
American Society for Pharmacology and Experimental Therapeutics
2 publications, 1.96%
Bentham Science
Bentham Science, 2, 1.96%
Bentham Science
2 publications, 1.96%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 2, 1.96%
Royal Society of Chemistry (RSC)
2 publications, 1.96%
Pleiades Publishing
Pleiades Publishing, 1, 0.98%
Pleiades Publishing
1 publication, 0.98%
IOS Press
IOS Press, 1, 0.98%
IOS Press
1 publication, 0.98%
Shi Jie Wei Chang Bing Xue Za Zhi She, 1, 0.98%
Shi Jie Wei Chang Bing Xue Za Zhi She
1 publication, 0.98%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 0.98%
Public Library of Science (PLoS)
1 publication, 0.98%
Biomedical Research Foundation, 1, 0.98%
Biomedical Research Foundation
1 publication, 0.98%
EManuscript Services, 1, 0.98%
EManuscript Services
1 publication, 0.98%
Japanese Society of Toxicology, 1, 0.98%
Japanese Society of Toxicology
1 publication, 0.98%
Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP)
Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP), 1, 0.98%
Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP)
1 publication, 0.98%
Spandidos Publications
Spandidos Publications, 1, 0.98%
Spandidos Publications
1 publication, 0.98%
5
10
15
20
25
30
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
YOKOYAMA Y. et al. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures // Biological and Pharmaceutical Bulletin. 2018. Vol. 41. No. 5. pp. 722-732.
GOST all authors (up to 50) Copy
YOKOYAMA Y., Sasaki Y., Terasaki N., Kawataki T., Takekawa K., Iwase Y., Shimizu T., Sanoh S., Ohta S. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures // Biological and Pharmaceutical Bulletin. 2018. Vol. 41. No. 5. pp. 722-732.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1248/bpb.b17-00913
UR - https://doi.org/10.1248%2Fbpb.b17-00913
TI - Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures
T2 - Biological and Pharmaceutical Bulletin
AU - YOKOYAMA, Yuichi
AU - Sasaki, Yoshifumi
AU - Terasaki, Natsuko
AU - Kawataki, Taku
AU - Takekawa, Koji
AU - Iwase, Yumiko
AU - Shimizu, Toshinobu
AU - Sanoh, Seigo
AU - Ohta, Shigeru
PY - 2018
DA - 2018/02/13 00:00:00
PB - Pharmaceutical Society of Japan
SP - 722-732
IS - 5
VL - 41
SN - 0918-6158
SN - 1347-5215
ER -
BibTex |
Cite this
BibTex Copy
@article{2018_YOKOYAMA
author = {Yuichi YOKOYAMA and Yoshifumi Sasaki and Natsuko Terasaki and Taku Kawataki and Koji Takekawa and Yumiko Iwase and Toshinobu Shimizu and Seigo Sanoh and Shigeru Ohta},
title = {Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures},
journal = {Biological and Pharmaceutical Bulletin},
year = {2018},
volume = {41},
publisher = {Pharmaceutical Society of Japan},
month = {feb},
url = {https://doi.org/10.1248%2Fbpb.b17-00913},
number = {5},
pages = {722--732},
doi = {10.1248/bpb.b17-00913}
}
MLA
Cite this
MLA Copy
YOKOYAMA, Yuichi, et al. “Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.” Biological and Pharmaceutical Bulletin, vol. 41, no. 5, Feb. 2018, pp. 722-732. https://doi.org/10.1248%2Fbpb.b17-00913.
Found error?